Semaglutide vs Tirzepatide: Weight Loss Showdown
Discover the key differences between Semaglutide and Tirzepatide in this comprehensive comparison of GLP-1 and dual agonist drugs for weight loss and diabetes.
Overview
Semaglutide and tirzepatide are the two top weekly shots for obesity and type 2 diabetes. Semaglutide is a GLP-1 receptor drug. Tirzepatide is the first dual GIP/GLP-1 receptor drug.
Both are taken once a week. But the dual action of tirzepatide usually gives more weight loss and better blood sugar control.
Semaglutide (Wegovy/Ozempic) is a GLP-1 drug. In trials, it led to about 15.8% weight loss. Tirzepatide (Zepbound/Mounjaro) is a dual GIP/GLP-1 drug. It reached up to 22.5% loss in SURPASS and SURMOUNT studies.
Tirzepatide vs Semaglutide Comparison
This tirzepatide vs semaglutide comparison covers weight loss, blood sugar, and safety.
- Semaglutide: GLP-1 only; lowers appetite, slows stomach emptying, and has proven heart benefit.
- Tirzepatide: GIP + GLP-1; adds more insulin release, better fat use, and often more weight loss.
How They Work
Semaglutide targets only the GLP-1 receptor. It raises insulin, lowers glucagon, slows stomach emptying, and cuts appetite.
Tirzepatide targets both GLP-1 and GIP receptors. GIP adds more insulin release, better fat use, and less nausea. That is why tirzepatide often gives more weight loss than GLP-1-only drugs.
Trial Results
- Semaglutide (STEP program): STEP 1 showed 14.9% loss at 68 weeks. STEP 5 showed 15.2% loss after 2 years. The SELECT heart trial found a 20% drop in major heart events in people with past heart disease.
- Tirzepatide (SURPASS for diabetes, SURMOUNT for obesity): SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks with the 15 mg dose, and 91% of people lost at least 5%. SURMOUNT-4 showed 26% loss over 88 weeks, even with a taper phase. In SURPASS-2, tirzepatide cut HbA1c by 2.0%-2.4% vs 1.6% with semaglutide.
Dosing Schedules
- Semaglutide (Wegovy): 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg weekly, with a dose increase every 4 weeks.
- Tirzepatide (Zepbound): 2.5 -> 5 -> 7.5 -> 10 -> 12.5 -> 15 mg weekly, with a dose increase every 4 weeks. The 5 mg dose often gives about 15% loss; higher doses help a bit more.
Both drugs need slow dose increases to limit stomach and gut side effects.
Side Effect Profiles
Both drugs mainly cause gut side effects: nausea, diarrhea, vomiting, constipation, and belly pain. These are most common when the dose is going up.
The GIP part of tirzepatide may partly cut GLP-1-related nausea, and stopping rates in trials were similar.
Rare risks for both include pancreatitis, gallbladder disease, and acute kidney injury, often from dehydration after vomiting. Both have boxed warnings for thyroid C-cell tumors based on rat data, and they should not be used in pregnancy or in people with MEN2/MTC history.
Cost & Availability
Both are brand-only in the U.S., with list prices around $1,000-1,200 per month. Tirzepatide has had fewer supply issues than semaglutide. Insurance coverage varies a lot. Medicare now covers anti-obesity drugs under the 2025 CMS expansion.
Which Should You Choose?
- For the most weight loss: Tirzepatide — up to 22.5% vs 15.8%.
- For proven heart benefit: Semaglutide, based on SELECT. The heart outcome trial for tirzepatide is still ongoing.
- For an oral drug: Semaglutide (Rybelsus, and oral Wegovy).
- For diabetes with the biggest HbA1c drop: Tirzepatide, at 2.0%-2.4% vs 1.6%-1.8%.
- For easy access: It depends on your region, insurance, and supply.
Both semaglutide and tirzepatide work best with diet, exercise, and close medical follow-up.
Related Peptides
Frequently Asked Questions
Does tirzepatide work better than semaglutide for weight loss?
Yes. In the semaglutide vs tirzepatide weight loss studies, SURMOUNT-1 showed up to 22.5% loss with tirzepatide, while semaglutide reached about 14.9%-15.8% in STEP studies. That is about 40%-50% more weight loss.
Which is better, semaglutide or tirzepatide?
It depends on your goal. If you want the most weight loss, tirzepatide is often the better choice. If you want proven heart benefit, semaglutide has the edge.
What makes tirzepatide a dual agonist?
Tirzepatide turns on both GIP and GLP-1 receptors. Semaglutide acts only on GLP-1. The GIP part may help weight loss and may reduce nausea a bit.
Which drug has proven heart benefits?
Semaglutide. The SELECT trial showed a 20% drop in major heart events. The heart outcome study for tirzepatide is still ongoing.
Can I take either drug by mouth?
Only semaglutide has an oral form. Rybelsus is for diabetes, and oral Wegovy is for weight loss. Tirzepatide is still injectable only.
Are the side effects different?
Both have similar gut side effects like nausea, vomiting, and diarrhea. Tirzepatide may cause a bit less nausea, but stopping rates are broadly similar.
References
- Jastreboff AM, et al. SURMOUNT-1: Tirzepatide Once Weekly for Obesity. N Engl J Med 2022;387:205-216.
- Garvey WT, et al. SURMOUNT-4: Tirzepatide for Weight Maintenance. JAMA 2023;329:1374-1385.
- Wilding JPH, et al. STEP 1: Semaglutide in Adults with Obesity. N Engl J Med 2021;384:989-1002.
- FDA Prescribing Information: Zepbound (tirzepatide) and Wegovy (semaglutide).